These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26977827)

  • 21. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
    Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
    J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.
    Bacha F
    Lancet Child Adolesc Health; 2019 Sep; 3(9):595-597. PubMed ID: 31345736
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
    Atonal-Flores B; León-Vázquez ML; Barranco-Juarez A
    Rev Med Inst Mex Seguro Soc; 2023 Jul; 61(4):489-495. PubMed ID: 37540652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
    Katsiki N; Ferrannini E
    J Diabetes Complications; 2020 Dec; 34(12):107723. PubMed ID: 32900588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lixisenatide for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):19-21. PubMed ID: 28118649
    [No Abstract]   [Full Text] [Related]  

  • 32. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
    Filchenko I; Simanenkova A; Chefu S; Kolpakova M; Vlasov T
    Diab Vasc Dis Res; 2018 Nov; 15(6):567-570. PubMed ID: 30024276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
    Hocher B; Tsuprykov O
    Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
    [No Abstract]   [Full Text] [Related]  

  • 35. Diabetes prescribing rises by a third over five years.
    Torjesen I
    BMJ; 2016 Oct; 355():i5484. PubMed ID: 27758791
    [No Abstract]   [Full Text] [Related]  

  • 36. Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
    Packer M
    J Card Fail; 2018 Feb; 24(2):109-111. PubMed ID: 29305970
    [No Abstract]   [Full Text] [Related]  

  • 37. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

  • 38. Update: Pediatric Diabetes.
    Gujral J; Sethuram S; Rapaport R
    J Diabetes; 2020 Mar; 12(3):262-264. PubMed ID: 31837125
    [No Abstract]   [Full Text] [Related]  

  • 39. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitagliptin for Type 2 diabetes: a 2015 update.
    Lee M; Rhee MK
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.